返回
Alphamab Oncology（09966.HK）價格
09966.HK 股價走勢圖
ALPHAMAB-B (09966.HK)
Alphamab Oncology
HK$9.35
-6.21%
$-0.62
盤中： Jan 20, 15:27:52 HKT
暫無資料Earnings FAQ
09966.HK 最近的每股盈餘與預期相比如何？
Alphamab Oncology 09966.HK 上一季度的收入表現如何？
Alphamab Oncology 的收入預期是多少？
Alphamab Oncology 的盈利品質評分是多少？
Alphamab Oncology 何時發布財報？
Alphamab Oncology 的預期收益是多少？
Alphamab Oncology 是否超出收益預期？
關鍵數據
前收市價
$9.82
開盤價
$9.97
當日範圍
$9.34 - $10.02
52週區間
$3.05 - $15.75
交易量
1.8M
平均成交量
2.5M
每股盈餘 (TTM)
0.27
股息收益率
--
市值
$9.0B
什麼是 ALPHAMAB-B？
Alphamab Oncology is an investment holding company. The company is headquartered in Suzhou, Jiangsu and currently employs 484 full-time employees. The company went IPO on 2019-12-12. The Company’s in-house pipeline consists of antibody-drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies in staggered development status in oncology. The Company’s product pipeline includes KN046 (PD-L1/CTLA-4 bispecific antibody), KN026 (HER2/HER2 bispecific antibody), KN035 (SubQ PD-L1), JSKN003 (HER2 biparatopic ADC), JSKN016(HER3/TROP2 bispecific antibody ADC), JSKN033(subcutaneous co-formulation of JSKN003 and KN035), used for indications such as 1L sq NSCLC, 1L HER2+ BC, 1L biliary track cancer, advanced solid tumors, HER2-expressing solid tumors and others.